{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,25]],"date-time":"2025-07-25T10:14:52Z","timestamp":1753438492036},"reference-count":35,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2008,2,14]],"date-time":"2008-02-14T00:00:00Z","timestamp":1202947200000},"content-version":"vor","delay-in-days":13,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Internal Medicine Journal"],"published-print":{"date-parts":[[2008,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The majority of patients with ulcerative colitis have disease involving only the distal colon. Although 5\u2010aminosalicylic acid (5\u2010ASA, mesalazine) and corticosteroids remain the important drugs used in the management of distal colitis and proctitis, recent expansion of delivery options of 5\u2010ASA and high level evidence regarding efficacy have led to a shift in treatment strategies. The availability of 5\u2010ASA in enema, foam and suppository formulations has enabled optimization of delivery of 5\u2010ASA to the affected mucosa. Such therapy has superior efficacy and fewer adverse effects compared with those of topical corticosteroids. Furthermore, rectal delivery is effective in the maintenance of remission. Consequently, new guidelines for the management of distal colitis have focussed more on rectal delivery and on optimizing 5\u2010ASA dosage than previously. However, corticosteroids remain an important remission\u2010inducing agent, and immune\u2010modulating drugs play a clear role in prevention of relapse and in managing chronically active disease. The changes in guidelines have raised several management questions, many of which are addressed in this review.<\/jats:p>","DOI":"10.1111\/j.1445-5994.2007.01601.x","type":"journal-article","created":{"date-parts":[[2008,2,15]],"date-time":"2008-02-15T01:17:29Z","timestamp":1203038249000},"page":"114-119","update-policy":"http:\/\/dx.doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Management of distal ulcerative colitis: frequently asked questions analysis"],"prefix":"10.1111","volume":"38","author":[{"given":"S. L.","family":"James","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P. M.","family":"Irving","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R. B.","family":"Gearry","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P. R.","family":"Gibson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2008,2,14]]},"reference":[{"key":"e_1_2_17_2_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.mib.0000231496.92013.85"},{"key":"e_1_2_17_3_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.mib.0000231495.92013.5e"},{"key":"e_1_2_17_4_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2000.02180.x"},{"key":"e_1_2_17_5_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.meg.0000131040.38607.09"},{"key":"e_1_2_17_6_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.mcg.0000139057.05297.d6"},{"key":"e_1_2_17_7_2","first-page":"135","volume-title":"Emerging Issues in Inflammatory Bowel Disease","author":"Gearry R","year":"2006"},{"key":"e_1_2_17_8_2","doi-asserted-by":"crossref","unstructured":"HommesDW.CMV co\u2010infection \u2013 does it matter?In:IrvingPM RamptonDS ShanahanF eds.Clinical Dilemmas in Inflammatory Bowel Disease. Oxford:Blackwell Publishing;2006;159\u201363.","DOI":"10.1002\/9780470750827.ch44"},{"key":"e_1_2_17_9_2","doi-asserted-by":"publisher","DOI":"10.1136\/gut.51.4.548"},{"key":"e_1_2_17_10_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2006.03058.x"},{"key":"e_1_2_17_11_2","article-title":"Oral 5\u2010aminosalicylic acid for maintenance of remission in ulcerative colitis","author":"Sutherland L","year":"2006","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_17_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(92)91601-4"},{"key":"e_1_2_17_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(98)70627-4"},{"key":"e_1_2_17_14_2","doi-asserted-by":"publisher","DOI":"10.1097\/00054725-200108000-00007"},{"issue":"2","key":"e_1_2_17_15_2","first-page":"A209","article-title":"A prospective blinded assessment of distal colonic mucosal concentrations of 5\u2010ASA and Nac\u20105\u2010ASA in ulcerative colitis patients treated with balsalazide (Colazal) or pH\u2010dependent mesalamine (Asacol)","volume":"130","author":"Kornbluth A","year":"2006","journal-title":"Gastroenterology"},{"key":"e_1_2_17_16_2","first-page":"714","article-title":"Clinical efficacy of mesalamine in the treatment of the spondyloarthropathies","volume":"27","author":"Thomson GT","year":"2000","journal-title":"J Rheumatol"},{"key":"e_1_2_17_17_2","article-title":"Balsalazide as alternative therapy to mesalamine dose\u2010escalation for acute, mild to moderate ulcerative colitis","volume":"122","author":"Pruitt R","year":"2002","journal-title":"Gastroenterology"},{"key":"e_1_2_17_18_2","article-title":"Oral 5\u2010aminosalicylic acid for induction of remission in ulcerative colitis","author":"Sutherland L","year":"2006","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_17_19_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2000.02185.x"},{"key":"e_1_2_17_20_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2004.40036.x"},{"key":"e_1_2_17_21_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2006.03071.x"},{"key":"e_1_2_17_22_2","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD000478.pub2"},{"key":"e_1_2_17_23_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2005.02331.x"},{"key":"e_1_2_17_24_2","article-title":"A single centre experience of methotrexate in the treatment of Crohn\u2019s disease and ulcerative colitis: a case for subcutaneous administration","author":"Nathan DM","year":"2007","journal-title":"J Gastroenterol Hepatol"},{"key":"e_1_2_17_25_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa050516"},{"key":"e_1_2_17_26_2","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-199921040-00006"},{"key":"e_1_2_17_27_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2006.00961.x"},{"key":"e_1_2_17_28_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2006.02639.x"},{"key":"e_1_2_17_29_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2002.05475.x"},{"key":"e_1_2_17_30_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2006.03186.x"},{"key":"e_1_2_17_31_2","first-page":"51","article-title":"Clinical ramifications of malabsorption of fructose and other short\u2010chain carbohydrates","volume":"31","author":"Barratt JS","year":"2007","journal-title":"Pract Gastroenterol"},{"key":"e_1_2_17_32_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2004.03.025"},{"key":"e_1_2_17_33_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2003.11.010"},{"key":"e_1_2_17_34_2","doi-asserted-by":"crossref","unstructured":"MpofuC WatsonAJ RhodesJM.Strategies for detecting colon cancer and\/or dysplasia in patients with inflammatory bowel disease.Cochrane Database Syst Rev2004; CD 000279. Review. Update in:Cochrane Database Syst Rev2006;(2):CD 000279.","DOI":"10.1002\/14651858.CD000279.pub2"},{"key":"e_1_2_17_35_2","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2003.035758"},{"key":"e_1_2_17_36_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2005.02700.x"}],"container-title":["Internal Medicine Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1445-5994.2007.01601.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1445-5994.2007.01601.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,15]],"date-time":"2023-10-15T16:25:52Z","timestamp":1697387152000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1445-5994.2007.01601.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,2]]},"references-count":35,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2008,2]]}},"alternative-id":["10.1111\/j.1445-5994.2007.01601.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1445-5994.2007.01601.x","archive":["Portico"],"relation":{},"ISSN":["1444-0903","1445-5994"],"issn-type":[{"value":"1444-0903","type":"print"},{"value":"1445-5994","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,2]]},"assertion":[{"value":"2008-02-14","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}